The combined application of PD-1 and CTLA-4 antibodies was initiated at an early stage and has been widely used in clinical practice with a profound lasting response rate and controllable AEs, which has significantly changed the treatment of advanced cancer [1]. This evidence concerns the gene CTLA4 and cancer.